ImmunoGen (IMGN) Shares are Down -4.96%

ImmunoGen (IMGN) : During the past 4 weeks, traders have been relatively bearish on ImmunoGen (IMGN), hence the stock is down -2.02% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.12% relative to the S&P 500. The 4-week change in the price of the stock is -2.55% and the stock has fallen -4.96% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.87% and the 50-Day Moving Average is 7.32%.The 200 Day SMA reached 57.58%

ImmunoGen

ImmunoGen (NASDAQ:IMGN): After opening at $2.66, the stock dipped to an intraday low of $2.6 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $2.75 and the buying power remained strong till the end. The stock closed at $2.68 for the day, a gain of 1.13% for the day session. The total traded volume was 1,718,413. The stocks close on the previous trading day was $2.68.

ImmunoGen (IMGN) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $9 and the lowest price target forecast is $3. The average forecast of all the analysts is $5.9 and the expected standard deviation is $2.41.

ImmunoGen, Inc. (ImmunoGen) is a clinical-stage biotechnology company focused on the development of targeted anticancer therapeutics. The Companys clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which is a type of medicine that uses a monoclonal antibody to deliver a therapeutic agent to targeted cells. The Company has three clinical-stage anticancer compounds: mirvetuximab soravtansine (IMGN853), coltuximab ravtansine, IMGN529, and IMGN779. The Companys partners are Amgen Inc., Bayer HealthCare (a subgroup of Bayer AG), Biotest AG, Eli Lilly and Company (Lilly), Novartis Institutes for BioMedical Research, Inc. (Novartis), the Roche Group, Sanofi and Takeda. The Companys collaborative partner compounds include Kadcyla, Indatuximab ravtansine, Isatuximab, Anetumumab ravtansine, AMG 595, AMG 172, SAR566658, SAR408701, LOP628 and PCA062. All of the Companys compounds are ADCs with the exception of isatuximab, which is a therapeutic antibody.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.